The primary efficacy outcome was the combined rate of death from a cardiovascular cause, heart attack, stroke due to inadequate blood supply, blood clots or amputation due to cardiovascular disease.
The trial enrolled 105 patients who had HFpEF causing shortness of breath and fatigue with ordinary or mild physical activity.
ANNEXA-4 is a global, single-arm, open-label clinical trial designed to evaluate andexanet alfa in patients who present with an acute major bleed while receiving apixaban, rivaroxaban, edoxaban or enoxaparin.
The ODYSSEY Outcomes trial (N=18,924) evaluated the effect of alirocumab on the occurrence of MACE in patients who had an ACS between 1-12 months prior to trial enrollment, and who were already taking maximally-tolerated statins (atorvastatin or rosuvastatin).
The results showed canagliflozin was associated with a significant reduction in risk of CV death or HHF by 22%.
After 30 days of treatment the analysis found that major bleeding - the most common complication with blood thinners - occurred at the same level (0.7%) for patients in both treatment groups